CompaniesOtherUpdated Oct 8, 2026
Matchpoint Therapeutics
Private. Matchpoint Therapeutics is a privately held biotechnology company based in Watertown, Massachusetts, developing breakthrough oral medicines for autoimmune and inflammatory diseases.
- Last round
- $150M Series B
- Backed by
- Nextech Invest
- Launched
- Not recorded
- People
- 10
Overview
Updated Oct 8, 2026
Every fact carries a numbered source. Where we can't source something, it says so.
Identity fields from the company record are sourced where a source is recorded; those have no number.
- Headquarters
- Watertown, Massachusetts · as of 2026-10-071
- Stage
- Series B · as of 2026-10-071
- Website
- matchpointtx.com opens in a new tab · as of 2026-10-072
- Sector
- Not recorded
- Geography
- Watertown, Massachusetts
- Founded
- Not recorded
Funding
How much has Matchpoint Therapeutics raised?
Rounds and backers, each sourced.
Rounds
Opportunities For accredited investors
Ways to invest in this company through an Alphaneo vehicle, when one exists. This section looks the same on every company page until you have an accredited profile.
Opportunities, terms and data rooms are shown to accredited investors. Creating a profile takes two minutes, and you’re notified first when anything opens.
No live opportunities right now. Accredited investors are notified first when one opens.
Create an accredited profileA vehicle is never smaller than $1,000,000.
People
Who founded and leads Matchpoint Therapeutics?
Names and titles only, each sourced.
- Nathanael Gray, PhDCo-founder; Professor of Chemical and Systems Biology at Stanford University3
- Tinghu Zhang, PhDFounder; Stanford University3
- Paola Castaldi, PhDSenior Vice President, Head of Platform and Chemical Biology2
- Wei Li, MDSenior Vice President, Immunology2
- Edward Chouchani, PhDCo-founder; Associate Professor of Cell Biology at Harvard Medical School and Dana-Farber Cancer Institute3
- Thomas Durand-Reville, PhDSenior Vice President, Drug Discovery2
- Christopher HrenSenior Vice President, Business Operations2
- Jared Cumming, PhDChief Scientific Officer2
- Jianwei Che, PhDFounder; Dana-Farber Cancer Institute3
- Andre TurennePresident & Chief Executive Officer2
Sources
Every claim on this page traces to one of these. The numbers match the citations above.
- 1Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases opens in a new tabHeadquarters, Stage, Funding · accessed Oct 8, 2026
- 2Matchpoint Therapeutics opens in a new tabWebsite, People · accessed Oct 8, 2026
- 3Matchpoint Therapeutics launches with $100 million to deliver on the promise of precision covalent medicines for immune diseases opens in a new tabFunding, People · accessed Oct 8, 2026